banner

Why choose a Clinically Documented CoQ10?


The absorption and the efficacy of CoQ10 supplements varies considerably depending on the formulation. CoQ10 supplements produced from the best CoQ10 raw material will give a poor absorption if the manufacturer has not used a proven formulation process.

Whether you are a consumer, a researcher or a medical doctor, you will want to use a CoQ10 supplement with documented absorption and proven effects in clinical studies.

A randomized controlled study completed in 2018 has shown that Pharma Nord's Bio-Quinone Active CoQ10 has double the absorption of the second best tested formulation and three to ten times better absorption than the other five tested formulations [Lopez-Lluch]. All products contained the same amount of CoQ10, but there was a statistically significant difference as to how much CoQ10 was absorbed from each product.

This is important because the CoQ10 cannot protect your heart muscle cells if it is not absorbed into the blood circulation.

The KiSel-10 and Q-Symbio studies document a protective effect of supplementation with Bio-Quinone Active CoQ10 on heart function in senior citizens and in heart failure patients respectively [Alehagen; Mortensen].

 

 

Follow in the Path of Leading CoQ10 Researchers
 

Researchers are becoming increasingly aware of the importance of using reliable and bioavailable products for clinical trials. Two large international CoQ10 clinical trials have stood out, not just because the researchers chose to use Pharma Nord's acclaimed CoQ10 product for their research, but because the clinical trials actually showed a statistically significant effect from CoQ10 supplementation in both cases. These clinical trials have helped emphasize the importance of selecting a CoQ10 product with documented bioavailability.

 

 

 

 

 

 

One of the clinical trials has been named KiSel-10 and was done by Swedish cardiologists from the University of Linköping and from the Karolinska Institute in Stockholm. The clinical trial results were published in 2014 in the International Journal of Cardiology.

The second clinical trial, Q-Symbio, was headed by the late cardiology researcher, Dr. Svend Aage Mortensen, from Rigshospitalet (state hospital) in Copenhagen and the results were published a year later in the Journal of the American College of Cardiology, Heart Failure, which is one of the world’s leading medical journals.

Clinical trials like these show that the Pharma Nord CoQ10 used is bioavailable and absorbed by participants. If it were not the case, there would not be a measurable effect from the CoQ10 supplementation as compared to the placebo group.
 

 

A Primary and a Secondary Endpoint from the Q-Symbio Study

 

 

 

MACE was a primary endpoint of the Q-Symbio study. This was an endpoint for which the study participants were randomized and for which the trial was powered.
All-cause Mortality was a secondary endpoint because this statistical analyse was not specified before the data was seen.

 

Ask your CoQ10 Manufacturer which Clinical Trials He or She has Supplied

Your CoQ10 manufacturer should be able to readily provide evidence about the clinical studied that were conducted using his or her CoQ10 formulation. These studies should show a significant and positive effect from the CoQ10 supplementation. Otherwise, it could be a sign that the manufacturer has not supplied any clinical studies or that the formulation provided had poor effect because it was not absorbed.

 

Ever since Pharma Nord launched its first CoQ10 product in 1991 (Bio-Qinon Q10 - in the US this product is named Bio-Quinone Active CoQ10 Gold), the manufacturer has made it a point to inform its consumers and the industry about the importance of using clinically documented products.

 

Pharma Nord always strives to encourage the individual consumer to ask us and other manufacturers for documentation. Bio-Quinone Active CoQ10 Gold has been involved in 78 human clinical trials, and we want you to know how it has performed in these independent and published clinical trials. Our message about quality and documentation has had a big influence on both consumers and researchers alike. At the end of the day, scientific research using a product the body cannot absorb has already failed before the product is ingested. In connection with products with absorption issues, we find it relevant to ask whether the clinical trials that were unable find any positive effects from CoQ10 supplementation simply were using poor products that were unabsorbable?

 

How to evaluate CoQ10 studies

 

What documentation will you expect from the CoQ10 supplement manufacturer? At the very least, you will want information about the following aspects of the scientific studies:

Publication: Where was the study published?

Methodology: Was the study a randomized, double-blind, placebo-controlled study? Such studies are the gold standard of experimental research.

Sample size: How many people participated in the study? How homogeneous were the study participants? It is difficult to generalize from the results of wildly heterogeneous studies.

Dosage: How many milligrams of CoQ10 did the study participants take each day? Were the CoQ10 doses taken with a meal? Were the CoQ10 doses divided throughout the day?

Duration: How long did the period of supplementation last?

Results: Did the blood CoQ10 concentrations in the active CoQ10 treatment group improve significantly better than in the placebo control group or in the comparison group?

Please remember: It all comes down to one thing and one thing only: Absorption. If the active ingredient never makes it into your bloodstream and from there into your cells, there is no way the product can have a positive effect.
 

Scientific references for Pharma Nord's Bio-Quinone Active CoQ10

Alehagen U, et al. Reduced Cardiovascular Mortality 10 Years after Supplementation with Selenium and Coenzyme Q10 for Four Years: Follow-Up Results of a Prospective Randomized Double-Blind Placebo-Controlled Trial in Elderly Citizens. PLoS One. 2015;10(12):e0141641.

López-Lluch G, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2018;57:133-140.

Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-9.

Weis M, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med. 1994;15 Suppl:s273-80.

Singh RB, et al. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors. 2005;25(1-4):219-24.

Folkers K, et al. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol Aspects Med. 1994;15 Suppl:s281-5.